Latest News

FDA approved risankizumab for children aged 6 years or older with plaque psoriasis or active psoriatic arthritis.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Frieden on expanding dupilumab use in pediatric skin conditions: prurigo nodularis, EB pruriginosa, and more.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Dawn Eichenfield, MD, PhD, discusses differential diagnosis, off-label treatment rationale, and multidisciplinary care for rare and atypical skin conditions in children.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

The US FDA has approved olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

Hear Anu Lala, MD, discuss how she turned a moment of childhood fascination into a lifelong career of caring for patients.

Katherine Tuttle, MD, discusses shifting the goals of chronic kidney disease management from slowing progression to preserving kidney function.

In the latest Skin of Color Savvy episode, Umayr Shaikh, MPH, shares how his work is shaping his medical career.

This episode covers the recent trial of the Signos weight loss platform, indicating weight loss that could challenge GLP-1 receptor agonists.

Siegfried discusses some of the most notable highlights of her session at the RAD 2026 conference regarding clinical pearls in dermatology.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

HCPLive previews Maui Derm NP+PA Summer 2026, covering sessions on atopic dermatitis, acne, psoriasis, pigmentation disorders, and more.

Panelists reached broad consensus that upfront dual oral combination therapy with an ERA and PDE5 inhibitor remains the foundational standard.

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

FDA cited manufacturing and labeling issues in its CRL for cytisinicline, with no clinical efficacy or safety deficiencies reported.

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

MOMENTUM data suggest hypercortisolism prevalence reached 43.6% among individuals with resistant hypertension and an eGFR below 45 mL/min/1.73 m².

Pediatric studies show dupilumab boosts height gains, eases caregiver-reported symptoms by week 2, and maintains strong skin clearance for 3 years.